NCT07282769

Brief Summary

This research study is testing the effectiveness and safety of semaglutide (Wegovy) in people with trichotillomania, also known as hair-pulling disorder.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for phase_2

Timeline
9mo left

Started May 2026

Shorter than P25 for phase_2

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress2%
May 2026Feb 2027

First Submitted

Initial submission to the registry

December 5, 2025

Completed
10 days until next milestone

First Posted

Study publicly available on registry

December 15, 2025

Completed
5 months until next milestone

Study Start

First participant enrolled

May 1, 2026

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2027

Last Updated

May 4, 2026

Status Verified

May 1, 2026

Enrollment Period

9 months

First QC Date

December 5, 2025

Last Update Submit

May 1, 2026

Conditions

Trichotillomania (Hair-Pulling Disorder)Hair-Pulling DisorderTrichotillomaniaHair Pulling DisorderHair Pulling

Keywords

trichotillomaniahair pulling

Outcome Measures

Primary Outcomes (1)

  • NIMH Trichotillomania Severity Scale

    Clinician-rated scale assessing trichotillomania symptom severity over the past week that will be administered at all visits. Total scores range from 0-20. Higher scores indicate greater severity.

    From screening to 1 week after last dose of study drug

Secondary Outcomes (2)

  • Clinical Global Impression-Improvement and Severity Scales

    From screening to 1 week after last dose of study drug

  • Massachusetts General Hospital Hair Pulling Scale

    From screening to 1 week after last dose of study drug

Study Arms (1)

Semaglutide (Wegovy)

EXPERIMENTAL

Participants will receive semaglutide (Wegovy) weekly for 8 weeks.

Drug: Semaglutide

Interventions

SemaglutideDRUG

All participants in the study will receive semaglutide (Wegovy).

Also known as: Wegovy
Semaglutide (Wegovy)

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Men and women age 18-75;
  • Diagnosis of current trichotillomania based on DSM-5 criteria and confirmed using the clinician-administered MIDI (13);
  • Hair pulling daily with urges to pull as the trigger in \>50% of the episodes of pulling;
  • Women of childbearing age are required to have a negative result on a beta-human chorionic gonadotropin pregnancy test;
  • Women of childbearing potential utilizing a medically accepted form of contraception defined as double barrier, oral contraceptive, injectable contraceptive, implantable contraceptive devices, and abstinence

You may not qualify if:

  • Infrequent pulling (i.e. less than daily) or automatic pulling (i.e. no urges to pull);
  • Unstable medical illness or clinically significant abnormalities on laboratory tests, EKG, or physical examination at screen as determined by the investigator;
  • History of seizures;
  • Myocardial infarction within 6 months;
  • Current pregnancy or lactation, or inadequate contraception in women of childbearing potential;
  • A need for medication other than semaglutide with possible psychotropic effects or unfavorable interactions as determined by the investigator;
  • Clinically significant suicidality (defined by the Columbia Suicide-Severity Rating Scale);
  • Lifetime history of bipolar disorder type I or II, schizophrenia, or any psychotic disorder;
  • Current skin picking disorder;
  • Initiation of psychotherapy or behavior therapy within 3 months prior to study baseline;
  • Initiation of psychotropic medications within 3 months prior to study baseline (stable doses will be allowed);
  • Previous treatment with semaglutide;
  • Use of any weight loss medications;
  • Body mass index (BMI, calculated as weight in kilograms divided by height in meters squared) less than 23;
  • Past-year substance use disorder other than tobacco use disorder or mild cannabis use disorder;
  • +4 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Trichotillomania

Interventions

semaglutide

Condition Hierarchy (Ancestors)

Obsessive-Compulsive DisorderAnxiety DisordersMental DisordersDisruptive, Impulse Control, and Conduct Disorders

Study Officials

  • Jon E Grant

    University of Chicago

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Megha Neelapu

CONTACT

773-702-5523megha.neelapu@bsd.uchicago.edu

Laurie Avila

CONTACT

773-702-5523Laurie.Avila@bsd.uchicago.edu

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 5, 2025

First Posted

December 15, 2025

Study Start

May 1, 2026

Primary Completion (Estimated)

February 1, 2027

Study Completion (Estimated)

February 1, 2027

Last Updated

May 4, 2026

Record last verified: 2026-05

Data Sharing

IPD Sharing
Will not share